EU Pancreas An Integrated European Platform for Pancreas Cancer Research – from Basic Science to Clinical and Public Health Interventions for a Rare Disease

• Published in: Community genetics Vol. 16; no. 6; pp. 305 - 312
• Main Authors: Milne, R., La Vecchia, C., Van Steen, K., Hahn, S., Buchholz, M., Costello, E., Esposito, I., Hoheisel, J.D., Lange, B., Lopez-Bigas, N., Michalski, C.W., Real, F.X., Brand, A., Malats, N.
• Format: Journal Article Web Resource
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.01.2013; Karger
• Subjects: Biomedical Research; Europe; Further Section; General & internal medicine; Health promotion; Human health sciences; Humans; Information Dissemination; International Cooperation; Multidisciplinary research; Médecine générale & interne; Pancreatic cancer; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - therapy; Public Health; Rare Diseases - diagnosis; Rare Diseases - therapy; Sciences de la santé humaine; Translational Research, Biomedical; Europe; ANE, Europe; Training and mobility; Rare disease; Data integration; Pancreas cancer; Early-stage researchers; COST Action BM1204; Public health; Omics data; Harmonization
• ISBN: 3318025720; 9783318025729
• ISSN: 1662-4246; 1662-8063; 1662-8063
• DOI: 10.1159/000355937

Background: Large-scale international collaboration is essential to decipher relevant information in the context of omics-scale interrogations in cancer research. This is even more important for rare and fatal diseases like pancreas cancer (PC). Methods: The COST Action BM1204 is a unique platform to facilitate the collaboration of a broad range of European and international PC multidisciplinary research groups in order to: (1) integrate knowledge and experience in a multidisciplinary way ‘from cell to society', (2) promote the application of uniform study tools and protocols, (3) foster their optimal use by early-stage researchers, (4) enhance the mobility and training of researchers, and (5) disseminate the results produced to the broader society. Results: This Action will develop novel interdisciplinary tools for collaborative research to improve our understanding of PC and its prevention, diagnosis and treatment. It also aims to answer questions related to the etiology, early detection, evidence-based and personalized treatment, and health management for PC. Furthermore, the Action will contribute to new insights into PC personalized medicine and beyond as well as to the understanding of complex and rare diseases taking PC as a best practice example. The Action aims at attracting young scholars across a range of disciplines in collaboration with more experienced researchers and enhancing active European participation in the international scenario of PC research. Conclusion: The ultimate aim is to foster PC research in Europe and to coordinate this effort with other international initiatives to reduce disease mortality.